Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ALMS vs RAPT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

RAPT Captures Overall Composite Edge (52.4 HOLD vs 43.3 HOLD), While ALMS Leads 4–1 on Growth & Valuation Pillars

RAPT Overall Winner 6-Pillar Tally: ALMS 4 – 1 RAPT (1 Tie) Matrix Metrics: ALMS 1 – 6 RAPT

As of Nov 16, 2026, RAPT Therapeutics, Inc. (RAPT) captures the overall head-to-head institutional edge over Alumis Inc. (ALMS) on higher Unified Composite conviction (52.4/100 HOLD vs. 43.3/100 HOLD) after splitting the core matrix 6–1 (led by Profitability & Quality), while ALMS wins 4–1 across the 6-pillar growth and valuation breakdown. ALMS trades at $5.04 (N/M Forward P/E, -5744.5% operating margin) versus RAPT at $58.02 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: RAPT earns the overall head-to-head edge with a stronger Unified Composite Score (52.4/100 HOLD vs. ALMS 43.3/100 HOLD) and -0.02β · 2% Vol risk profile, whereas ALMS leads top-line expansion (-37.7% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: ALMS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.8); meanwhile RAPT trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 79.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ALMS vs RAPT
ALMS NASDAQ
Alumis Inc. Common Stock
Pharmaceutical Preparations
$5.04
-9.91% 1D
Market Cap $793.4M
TTM Revenue $7.4M
Forward P/E N/M
Beta / 30D Vol 2.23β · 85% Vol
Unified Composite Score
43.3 / 100 HOLD
Tech 20.0 Fund 51.0 Flow 67.0 Mom 74.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -45.8%), weak momentum, RSI 30
RSI-14: 29.8 · SMA20: $6.43 · SMA50: $7.12
RAPT NASDAQ Head-to-Head Winner
RAPT Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$58.02
+0.07% 1D
Market Cap $1.7B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -0.02β · 2% Vol
Unified Composite Score
52.4 / 100 HOLD
Tech 40.0 Fund 46.0 Flow 61.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (27.1% over 20 days), RSI 80
RSI-14: 79.7 · SMA20: $57.82 · SMA50: $47.67

6-Pillar Scorecard Institutional Category Breakdown (ALMS 4 – 1 RAPT)

Columns: Metric · ALMS · RAPT
1. Valuation Multiples ALMS
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 103.6x N/M
2. Growth & Scale ALMS
Revenue Growth (YoY) -37.7% -100.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $7.4M N/A
Market Cap $793.4M $1.7B
3. Profitability & Quality RAPT
Gross Margin 100.0% N/A
Operating Margin -5744.5% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -93.7% -85.4%
4. Balance Sheet & Cash Flow ALMS
Cash Generation (TTM) -$352M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $27M Net Cash $9.02 Book/Sh · -85.4% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ALMS
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 80.0% (8th %ile) 0.8% (<1st %ile)
Put/Call OI Skew 4433.18x (Put-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ALMS (1) vs RAPT (6)
Institutional Metric ALMS RAPT Criterion Row Edge
Market Capitalization
Scale
$793.4M $1.7B Larger Scale RAPT
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-37.7% -100.0% Higher Growth ALMS
Operating Margin (TTM)
Profitability
-5744.5% 0.0% Higher Margin RAPT
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-93.7% -85.4% Higher ROE RAPT
52-Week Range Position
Momentum
2% ($5–$31) 100% ($1–$58) Stronger Trend RAPT
Beta / 30D Volatility
Risk Regime
2.23β · 85% Vol -0.02β · 2% Vol Lower Realized Risk RAPT
Unified Institutional Score
Composite Signal
43.3 / 100 (HOLD) 52.4 / 100 (HOLD) Higher Composite RAPT
Trailing 12M Revenue (USD)
Operating Scale
$7.4M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 103.6x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$352M ($27M Net Cash) N/A ($9.02 Book/Sh · -85.4% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ALMS +10.05 pp
ALMS: +10.73% · RAPT: +0.68%
3M Horizon ALMS +214.57 pp
ALMS: +289.01% · RAPT: +74.44%
6M Horizon ALMS +336.46 pp
ALMS: +438.41% · RAPT: +101.95%
1Y Horizon ALMS +336.46 pp
ALMS: +438.41% · RAPT: +101.95%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ALMS vs RAPT. Trailing 12-month operating profitability (ALMS -5744.5% vs RAPT 0.0%) and valuation multiples (ALMS N/M vs RAPT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ALMS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$7.4M
Gross Margin100.0%
Op. Margin-5744.5%
ROE / Fwd P/E-93.7% · N/M
RAPT ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-85.4% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ALMS BREAKDOWN
91d in phase · OBV NEUTRAL
Current IV 80.0%
IV Percentile 8th %ile
Put/Call OI Skew 4433.18x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact ALMS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RAPT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 0.8%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RAPT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ALMS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $793.4M market capitalization and -5744.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
RAPT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.7B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ALMS vs RAPT Key Questions & Quantitative Answers

As of Nov 16, 2026, RAPT Therapeutics, Inc. (RAPT) captures the overall head-to-head institutional edge over Alumis Inc. (ALMS) on higher Unified Composite conviction (52.4/100 HOLD vs. 43.3/100 HOLD) after splitting the core matrix 6–1 (led by Profitability & Quality), while ALMS wins 4–1 across the 6-pillar growth and valuation breakdown. ALMS trades at $5.04 (N/M Forward P/E, -5744.5% operating margin) versus RAPT at $58.02 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: RAPT earns the overall head-to-head edge with a stronger Unified Composite Score (52.4/100 HOLD vs. ALMS 43.3/100 HOLD) and -0.02β · 2% Vol risk profile, whereas ALMS leads top-line expansion (-37.7% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ALMS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.8); meanwhile RAPT trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 79.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ALMS leads the Growth & Scale pillar: ALMS posts -37.7% YoY revenue growth and +0.0% YoY earnings growth on $7.4M TTM revenue (100.0% gross margin, -5744.5% operating margin), compared with RAPT at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ALMS generates $7.4M in USD-normalized revenue versus N/A for RAPT. In operating R&D and SG&A reinvestment, ALMS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for RAPT.

ALMS screens cheaper on headline valuation multiples. ALMS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 103.6x EV/Revenue (unreported FCF margin), whereas RAPT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ALMS (-93.7% ROE) versus RAPT (-85.4% ROE) capital efficiency.

In options market volatility and institutional positioning, ALMS carries 80.0% implied volatility (8th %ile, Compressed (<25th %ile)), a 4433.18x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.23β · 85% Vol realized risk). By comparison, RAPT carries 0.8% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.02β · 2% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.